Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era

Overview

Journal Cell Stem Cell

Publisher Cell Press

Specialty Cell Biology

Date 2017 Nov 4

PMID 29100010

Citations 165

Authors

Roger A Barker

Malin Parmar

Lorenz Studer

Jun Takahashi

Affiliations

Soon will be listed here.

Abstract

Stem cell-based therapies for Parkinson's disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As many groups have ongoing or completed GMP-level cell manufacturing, we highlight key clinical translation considerations from our recent fourth GForce-PD meeting.

Citing Articles

Long-Term Engraftment of Cryopreserved Human Neurons for In Vivo Disease Modeling in Neurodegenerative Disease.

Marmion D, Deng P, Hiller B, Lewis R, Harms L, Cameron D Biology (Basel). 2025; 14(2).

PMID: 40001985 PMC: 11852092. DOI: 10.3390/biology14020217.

NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson's model.

Alecu J, Sigutova V, Brazdis R, Lorentz S, Bogiongko M, Nursaitova A BMC Neurosci. 2025; 26(1):8.

PMID: 39875842 PMC: 11773751. DOI: 10.1186/s12868-025-00926-y.

Cell therapy for neurological disorders.

Svendsen S, Svendsen C Nat Med. 2024; 30(10):2756-2770.

PMID: 39407034 DOI: 10.1038/s41591-024-03281-3.

Organoids and chimeras: the hopeful fusion transforming traumatic brain injury research.

Bellotti C, Samudyata S, Thams S, Sellgren C, Rostami E Acta Neuropathol Commun. 2024; 12(1):141.

PMID: 39215375 PMC: 11363608. DOI: 10.1186/s40478-024-01845-5.

The history and status of dopamine cell therapies for Parkinson's disease.

Barker R, Bjorklund A, Parmar M Bioessays. 2024; 46(12):e2400118.

PMID: 39058892 PMC: 11589688. DOI: 10.1002/bies.202400118.